Only when we functionalize the entire network can we begin to treat individual patients with rational drug combinations based on
their unique tumor genome — the promise of personalized medicine.
Not exact matches
Rather,
tumors arise from the complex interplay between any number of mutually exclusive abnormal changes in the
genome, the combinations of which can be
unique to each individual patient.
The blood test, based on the
unique genetic fingerprint contained within the
genome of every cancer, can not only detect the presence of
tumor, but track its progress.
Tumor cells carry a
unique set of mutations in its
genome that alter normal cell functions.